Get the Stockscreener App
211.59
2.53%
5.22
Pre-market:
210.59
-1.00
-0.47%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $211.59, with a volume of 4.64M.
It is up +2.53% in the last 24 hours and down -8.05% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$206.37
Open:
$206.26
24h Volume:
4.64M
Relative Volume:
0.64
Market Cap:
$374.25B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
89.60
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-1.58%
1M Performance:
-8.05%
6M Performance:
-8.50%
1Y Performance:
+20.45%
1-Day Range:
$204.56
$212.22
1-Week Range:
$201.66
$214.56
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
211.59 | 374.25B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
953.30 | 851.64B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
241.30 | 581.20B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
204.27 | 316.79B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
123.18 | 304.55B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Lobbying Update: $80,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
Exclusive: AbbVie sues to narrow drug discount patient definition - Axios
AbbVie Dividend Growth & Portfolio Outlook 2026News and Statistics - IndexBox
AbbVie Says 340B Program Defines 'Patient' Too Broadly - Law360
AbbVie files lawsuit to address 'outdated' drug discount eligibility program - Reuters
AbbVie Sues US Over Patients Eligible for Drug Discount Program - Bloomberg Law News
Buying pressure lifts AbbVie stock higher in today's trading - Traders Union
AbbVie sues to narrow 340B eligibility - FirstWord Pharma
AbbVie (ABBV) Challenges Government's Drug Discount Program Defi - GuruFocus
AbbVie : moves to close loopholes and strengthen accountability in 340B program - marketscreener.com
Abbvie Files Lawsuit To Address 340B Program Guidance - TradingView
AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal (NYSE:ABBV) - Seeking Alpha
ABBV: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Cantor Fitzgerald lowers Abbvie stock price target on valuation - Investing.com
BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year - AbbVie News Center
AbbVie Stock Review 2026: Earnings Outlook, Dividend Yield, and ValuationNews and Statistics - IndexBox
Ethos Capital Buys Stake in AbbVie - National Today
Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story? - Yahoo Finance
AbbVie: Lowered Guidance Is Just NoiseReiterate Buy - Seeking Alpha
AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges - Intellectia AI
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade - Yahoo Finance
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade - The Motley Fool
Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin - Investing News Network
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns - AOL.com
Hidradenitis Suppurativa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte Corp, CSL - Barchart.com
Austin gets Allergan training hub for injectables and skincare - Stock Titan
AbbVie (ABBV) Gets a Buy from Scotiabank - The Globe and Mail
Should you buy AbbVie stock before April 29? - MSN
69,065 Shares in AbbVie Inc. $ABBV Acquired by Robinhood Asset Management LLC - MarketBeat
Should You Buy AbbVie Stock Before April 29? - The Motley Fool
J.P. Morgan Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $260 - Moomoo
TrumpRx adds medicines from AbbVie and Roche’s Genentech: report - Seeking Alpha
AbbVie Inc. $ABBV Shares Sold by Sound Income Strategies LLC - MarketBeat
Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation - Yahoo Finance
Albion Financial Group UT Trims AbbVie Inc. Stake - National Today
AbbVie Inc. $ABBV Stake Lowered by Albion Financial Group UT - MarketBeat
AbbVie Inc. (ABBV) latest stock news and headlines - Yahoo Finance Australia
AbbVie Inc. (ABBV) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie (ABBV) to Offer Humira at Significant Discount on TrumpRx Platform - GuruFocus
AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge - MSN
2 more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx - CBS News
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AbbVie (NYSE:ABBV) Stock Price Down 1.1%Time to Sell? - MarketBeat
Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH - Benzinga
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation (NYSE:ABBV) - Seeking Alpha
High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout - Yahoo Finance
Parkinson’s Disease Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics - Barchart.com
9 Newly Overvalued Stocks this Week - Morningstar
AbbVie Forecasts $744M Pipeline Charge, Cuts 2026 Guidance - Hoodline
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):